AbbVie maintained at Overweight by Morgan Stanley
Morgan Stanley maintained its Overweight rating on AbbVie, according to Benzinga’s ratings action recap.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Morgan Stanley raises AbbVie price target to $310
Morgan Stanley raised its AbbVie price target to $310 from $296, maintaining an Overweight rating, per Benzinga.